Emerging Role of Myeloperoxidase in the Prognosis of Nephrotic Syndrome Patients Before and After Steroid Therapy.

Abstract

BACKGROUND:

Myeloperoxidase (MPO) is a myelocyte derived iron containing enzyme particularly involved in host defense by destroying foreign micro organisms invading the body. Numerous evidences suggest that MPO is involved in the pathogenesis of many inflammatory diseases, especially atherosclerosis.

AIM:

Present study deals with the role of MPO in the renal function and progression of disease in Nephrotic syndrome patients.

STUDY DESIGN AND SETTINGS:

Case- Control Study carried out in Kasturba Medical College Hospital, Mangalore, India.

MATERIALS AND METHODS:

Forty newly diagnosed Nephrotic syndrome cases, 40 age and sex matched healthy controls and 15 subjects in Nephrotic syndrome remission, were included in the study. Myeloperoxidase enzyme was assayed by 4 amino antipyrine methods in all the subjects. Other renal parameters like urea, creatinine, Blood Urea Nitrogen (BUN), BUN- Creatinine ratio (BUN/Cr) total protein, albumin, globulin, albumin - globulin ratio (A/G ratio) and estimated Glomerular Filtration Rate (eGFR) were also analysed. 24 hour urine protein-creatinine ratio was estimated in Nephrotic syndrome cases and remission group by turbidimetric assay.

STATISTICAL ANALYSIS:

Students paired t-test and Wilcoxon Signed Rank test were used for the comparison of the data. Pearson and Spearman analyses were used for correlation of the parameters.

RESULTS:

MPO levels were found to be high in Nephrotic syndrome cases when compared to healthy controls. Urea, creatinine, BUN, BUN/Cr ratio and eGFR were high in Nephrotic syndrome cases while total protein, albumin, globulin and A/G ratio showed decreased levels. MPO had a positive correlation with creatinine and urine protein-creatinine ratio in Nephrotic syndrome. During remission, MPO levels decreased significantly while total protein and albumin levels increased.

CONCLUSION:

Myeloperoxidase enzyme is found to be elevated and it strongly correlated with the severity of disease in Nephrotic syndrome. Further studies can be done to use MPO as a therapeutic target in Nephrotic syndrome to ameliorate the symptoms.

• Authors: Sreelatha Souparnika, Benedicta D'Souza, Vivian D'Souza, Sushanth Kumar, Poornima Manjrekar, Manohar Bairy, Rajeevalochana Parthasarathy, Srinivas Kosuru
• Journal: Journal of clinical and diagnostic research : JCDR (J Clin Diagn Res) Vol. 9 Issue 7 Pg. BC01-4 (Jul 2015) ISSN: 2249-782X [Print] India
• PMID: 26393116 (Publication Type: Journal Article)